Introduction
Materials and methods
Search strategy for identification of studies
Inclusion and exclusion criteria
Methodological quality (risk of bias) assessment
Data extraction
Overlapping datasets
Data synthesis and analyses
Results
Search results and included studies
Authors, publication year | Study type | Study population | DKI acquisition technique | DKI processing | Reference Standard | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients’ no. | Mean age (year) | Histologic types, (n) | Molecular types, (n) | Recurrent cases (n) | Machine, strength | DKI:TR/TE (ms) | b value no. | Max b value(s/mm2) | Diffusion directions (n) | ROI, sequence used | Normalisation | DKI parameter/s | Time interval (days) | |||
Hempel et al. 2017 | Prospective | 60 | 51.4 ± 14.6 | AS II(17), AS III(15), AS IV(12), OD II(11), OD III(5) | IDH mut AS (22), IDH wt GBM (22), 1p/19q OD (16) | None | Siemens, 3T | 5900/95 | 6 | 2500 | 30 | Whole solid tumour, FLAIR | cNAWM | MK | 14 | Histologic and immunohistochemistry (IDH, ATRX) examination (WHO 2016) |
Hempel et al. 2017 | Prospective | 77 | 51.3 ± 15.3 | AS II(17), AS III(19), AS IV(19), OD II(15), OD III(7) | IDH mut AS (25), IDH wt GBM(30), 1p/19q OD(22) | None | Siemens, 3T | 5900/95 | 6 | 2500 | 30 | Whole solid tumour, FLAIR | None | MK | 14 | Histologic and immunohistochemistry examination (WHO 2016) |
Hempel et al. 2017 | Prospective Data | 77 | 51.3 ± 15.3 | AS II(17), AS III(19), AS IV(19), OD II(15), OD III(7) | IDH mutant AS (25), IDH wild type GBM (30), 1p/19q LOH OD (22) | None | Siemens, 3 T | 5900/95 | 6 | 2500 | 30 | Whole solid tumour, FLAIR | NA | Perfusion biased and corrected MK | 14 | Histopathology and immunohistochemistry (WHO 2016) |
Maximov et al. 2017 | Retrospective | 24 | Range (18–59) | AS II(8), AS III(8), IV(8) | None | None | GE, 3 T | 10,000/103.4 | 3 | 2500 | 60 | Whole solid tumour, NA | cNAWM | MK, Kr, Ka | 7–14 | Histopathologic examination (WHO 2007) |
Qi et al. 2017 | Retrospective | 163 | 40.5 ± 11.5 | II(63), III(48), IV(52) | None | None | Siemens, 3 T | 3600/76 | 3 | 2000 | 32 | Whole solid tumour, T2WI | cNAWM | MK, Kr, Ka | 21 | Histopathologic examination (WHO 2007) |
Qi et al., 2017 | Retrospective | 39 | LGG(40.08), HGG(54.35) | HGG(26), LGG(13) | None | None | Siemens, 3 T | 6000/98 | 3 | 2000 | 30 | Whole solid tumour, diffusion maps | NA | MK,KFA | NA | Histopathologic examination (WHO 2007) |
Delgado et al. 2017 | Prospective | 35 | 48 ± 15 | AS II(10), AS III(8), OD II(13), OD III(4) | None | None | Philips, 3 T | 5400/76 | 5 | 2750 | 15 | Whole, centre, peripheral tumour, FLAIR | None | Mk, Kr, Ka | NA | Histopathologic examination (WHO 2007) |
Hempel et al. 2016 | Prospective | 50 | 49.9 ± 14.2 | II(25), III(15), IV(10) | IDH mut (19), IDH wt (15) | 16 | Siemens, 3T | 5900/95 | 6 | 2500 | 30 | Whole solid tumour, FLAIR, T2WI | cNAWM | MK | 14 | Histologic and immunohistochemistry (WHO 2016) |
Li et al. 2016 | Retrospective | 37 | 47 | LGG(16), HGG(21) | None | None | Siemens, 3 T | 3000/109 | 6 | 2500 | 30 | Centre, peripheral tumour, T2,T1 + C | cNAWM | MK | 7 | Histopathologic findings (WHO 2007 & KI 67, TVA, TCD) |
Tan et al. 2016 | Retrospective | 60 | 49.6 HGA = 55.6, LGA = 40.2 | HGA(35), LGA(25) | None | None | GE, 3 T | 6500/11 | 3 | 2000 | 30 | Whole solid tumour, FLAIR, T2, ADC | cNAWM | MK, Kr, Ka | NA | Histopathology (2007) and aquaporin 4 expression |
Raja et al. 2016 | Retrospective | 53 | Range = 20–67 | II(19), III(20), IV(14) | None | None | Philips, 3 T | 4000/104 | 3 | 2500 | 15 | Whole solid tumour, T2WI | NA | Mk,Kr, Ka, FAK, | NA | Histopathologic (WHO 2007) |
Jiang et al. 2015 | Prospective | 74 | 41.36 ± 14.01 | I(3), II(31), III(19), IV(21) | None | 7 | GE, 3 T | 6500/85 | 4 | 2500 | 25 | Whole solid tumour, T1 + C | cNAWM | MK, Kr, Ka | 25 | Histopathologic (WHO 2007) including Ki 67 |
Bai et al. 2015 | Prospective | 62 | 46 | AS II(15), OD II(8), OAS II(5), OD III(2), OAS III(5), AS III(8), IV(19) | None | None | GE, 3 T | 7000/80 | 6 | 2500 | 25 | Whole solid tumour, ADC | NA | MK | 10 | Histopathologic ex WHO 2007 |
Tietze et al. 2015 | Retrospective | 34 | NA | HGG(22), LGG(12) | None | 2 | Siemens, 3 T | 10,300/100 | 3 | 2500 | 9 | Centre, peripheral tumour, FLAIR, T1 + C | cNAWM | MK’(fast MK) | NA | Histopathologic examination WHO-2007 |
Cauter et al. 2014 | Prospective | 35 + 19 (validation) | Median age: 55 | HGG(21), LGG(14) | None | None | Philips, 3 T | 3200/90 | 3 | 2800 | 25, 40, 75 | Whole solid tumour, T2WI | NA | MK | 19 | Histopathologic examination (WHO 2007) |
Cauter et al. 2012 | Prospective | 27 | 54,HGG = 61, LGG = 42 | HGG(17), LGG(11) | None | None | Philips, 3 T | 3200/90 | 3 | 2800 | 25,40,75 | Whole solid tumour, T2WI | cNAWM, PLIC | MK, Ka, Kr | 28 | Histopathologic ex WHO-2007, (4 patients depended on PET) |
Raab et al. 2010 | Prospective | 34 | 56 | AS II(5), AS III(13), IV(16) | None | None | Siemens, 3 T | 2300/109 | 6 | 2500 | 30 | Whole solid tumour, T2WI | cNAWM | MK | 21 | Histopathologic examination WHO-2007 |
Pang et al. 2016 | Prospective | 31 | 49.2 | HGG(20), B lymphoma (11) | None | None | GE, 3 T | 5000/90 | 3 | 2500 | 5, 25, 25 | Whole solid tumour, FLAIR, T1 + C | cNAWM | MK, Ka, Kr | 6 | Histopathology examination (WHO 2007) |
Tan et al. 2015 | Retrospective | 51 | AS: 56.6, metastasis: 60.1 | HGA(31), solitary metastasis (20) | None | None | GE, 3 T | 6500/115 | 3 | 2000 | 30 | Whole solid tumour, T1 + C | cNAWM | MK, Kr, Ka | NA | Histopathologic examination WHO 2007 |